John Van Der Wielen appointed to drive pharmaceutical innovation

John Van Der Wielen's recent appointment to the Board of Bridgewest Perth Pharma has sparked excitement in the pharmaceutical industry. With a rich background in corporate strategy and a history of driving growth and innovation, Van Der Wielen brings a wealth of experience to his new role.

Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group, praised Van Der Wielen's expertise, highlighting the potential for expansion and exploration of new opportunities in the pharmaceutical sector.

Van Der Wielen, who currently serves as Chair for Orthocell Ltd. and Crown Resorts Perth, has a strong track record in various organizations, including the Future Health Innovation and Research Fund WA and the Royal Flying Doctor Service (WA).

Expressing his enthusiasm for joining Bridgewest Group and Bridgewest Perth Pharma, Van Der Wielen emphasized the growth potential in the pharmaceutical sector and the opportunity to contribute to Australia's business economy as a global exporter of quality medical products.

Bridgewest Group, a renowned private equity firm focusing on life sciences and biotech investments, has made significant contributions to the industry, including investments in the Pfizer Perth facility, creating new pharmaceutical manufacturing jobs and enhancing drug supplies in the region.

With a commitment to excellence and innovation, Bridgewest Perth Pharma aims to lead the way in healthcare advancements, solidifying its position as a key industry player.

Founded in 1999, Bridgewest Group is a global investment firm known for its success in creating and scaling businesses in key sectors such as Life Sciences, Software, Semiconductor, and Artificial Intelligence/Deep Tech. The firm's diverse portfolio and financial services support its mission to drive growth and success.

Bridgewest Perth Pharma, a subsidiary of Bridgewest Group, operates through its divisions, NovaCina and LumaCina, focusing on drug manufacturing and pharmaceutical marketing. By leveraging innovative technologies and a skilled workforce, the company aims to meet the rising demand for high-quality therapeutics.

John Van Der Wielen's appointment to Bridgewest Perth Pharma signifies a strategic move towards further growth and innovation in the pharmaceutical sector. With Bridgewest Group's commitment to excellence and Bridgewest Perth Pharma's focus on cutting-edge healthcare solutions, the industry can expect exciting developments ahead.